Maria Piron

Dr. Maria Piron

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MLMeritxell Llorens-Revull
Meritxell Llorens-Revull
BMBrenda Martínez-González
Brenda Martínez-González
JQJosep Quer
Josep Quer
JEJuan Ignacio Esteban
Juan Ignacio Esteban
GNGonzalo Núñez-Moreno
Gonzalo Núñez-Moreno
Maria I. CostafredaMaria I. Costafreda
Maria I. Costafreda
MicroRNAs (miRNAs) encapsulated in extracellular vesicles (EVs) are potential diagnostic and prognostic biomarkers. However, discrepancies in miRNA patterns and their validation are still frequent due to differences in sample origin, EV isolation, and miRNA sequencing methods. The aim of the present study is to find a reliable EV isolation method for miRNA sequencing, adequate for clinical application. To this aim, two comparative studies were performed in parallel with the same human plasma sample: (i) isolation and characterization of EVs obtained using three procedures: size exclusion chromatography (SEC), iodixanol gradient (GRAD), and its combination (SEC+GRAD) and (ii) evaluation of the yield of miRNA sequences obtained using NextSeq 500 (Illumina) and three miRNA library preparation protocols: NEBNext, NEXTFlex, and SMARTer smRNA-seq. The conclusion of comparison (i) is that recovery of the largest amount of EVs and reproducibility were attained with SEC, but GRAD and SEC+GRAD yielded purer EV preparations. The conclusion of (ii) is that the NEBNext library showed the highest reproducibility in the number of miRNAs recovered and the highest diversity of miRNAs. These results render the combination of GRAD EV isolation and NEBNext library preparation for miRNA retrieval as adequate for clinical applications using plasma samples.

10 April 2019 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
CSClive R. Seed
Clive R. Seed
JAJean‐Pierre Allain
Jean‐Pierre Allain
MLMiquel Lozano
Miquel Lozano
SLSyria Laperche
Syria Laperche
PGPierre Gallian
Pierre Gallian
MSMichael Schmidt
Michael Schmidt

6 September 2022 in Viruses
Verified
Journal Article
Open access
PDF file
MPMaria Piron
Maria Piron
Fernando SalvadorFernando Salvador
Fernando Salvador
ECEstrella Caballero
Estrella Caballero
AMAdrian-Sanchez Montalva
Adrian-Sanchez Montalva
MBMarta Bes
Marta Bes
SSSILVIA SAULEDA
SILVIA SAULEDA
Human T-cell lymphotropic virus type 1 and 2 (HTLV-1/2) screening is not mandatory in Spanish blood banks. In Catalonia, selective screening was introduced in 2008, followed by universal screening in 2011. We present herein a 10-year experience of HTLV testing in blood donors. HTLV-1/2 selective screening was performed using Ortho-Clinical Diagnostics HTLV-I/HTLV-II Ab-Capture ELISA between February 2008 and May 2009, then Abbott Prism HTLV-I/ HTLV-II assay until December 2010. Abbott Architect rHTLV-I/II assay was then used for HTLV-1/2 universal screening in pooled samples. INNO-LIA HTLV I/II Score (Fujirebio) and in-house HTLV-1/2 proviral DNA real-time PCR were used in reactive samples. Follow-up was offered to confirm HTLV-1/2 donors in Vall d’Hebron Hospital. Between 2008 and 2017, 51 blood donors were confirmed HTLV positive (46 HTLV-1, 4 HTLV-2 and 1 HTLV) out of 2,114,891 blood donations (1 in 41,468). Sixty-nine percent were female, median age was 40 years and most were born in Latin America (69%), followed by Europe (25%), Africa (4%) and Asia (2%). Screening of relatives and partners identified 12 additional HTLV-1 cases. Lookback studies did not show any HTLV-1/2 transmission. HTLV infections found in blood donors mirror epidemiological changes in the population of Spain. Consequently, HTLV should be considered a potential risk for recipients and calls for the design of optimal strategies to ensure transfusion safety.

4 November 2025 in Transfusion
Verified
Journal Article
Open access
TJTeresa Jimenez‐Marco
Teresa Jimenez‐Marco
MPMaria Piron
Maria Piron
GCGabriela Capllonch‐Amer
Gabriela Capllonch‐Amer
MBMarta Bes
Marta Bes
JLJeffrey M. Linnen
Jeffrey M. Linnen
SSSILVIA SAULEDA
SILVIA SAULEDA
Background: Considering the increase of West Nile virus (WNV) circulation in Europe, blood banks perform WNV Nucleic Acid Test testing to ensure transfusion safety during the WNV transmission season. Usutu virus (USUV), an arbovirus related to WNV, has relevant molecular and serological cross‐reactivity with WNV. Study Design and Methods: During the 2024 WNV season in Europe, 15,957 blood donations from the Balearic Islands Blood Bank and 79,400 from the Catalonia Blood Bank were tested for WNV using the Cobas WNV real‐time PCR (Roche Diagnostics, USA) and the Procleix WNV/Procleix ArboPlex transcription‐mediated assays (Grifols Diagnostic Solutions Inc., USA), respectively. Serological tests for flavivirus, PCR using USUV‐ and WNV‐specific primers, sequencing of viral RNA, and neutralization tests (NT) were performed to confirm positive results. Results: We identified three donors with USUV infection. In July, the first donor was detected in Majorca (Balearic Islands), whose infection was confirmed by NT. In September, two donors with USUV Africa 3 lineage were identified by RT‐PCR and sequencing in Catalonia. There were three USUV‐positive cases in 95,357 donations (1 in 31,786; 95% CI: 1 in 10,877 to 1 in 154,083) during the 2024 WNV season in Spain. Discussion: We report three cases of autochthonous USUV infection in blood donors from the Balearic Islands and Catalonia, two of which were infected by the USUV Africa 3 lineage. Health authorities should be aware that positive WNV screening may be due to USUV, an emerging zoonotic virus that can be underreported.


8 December 2021 in Vox Sanguinis
Verified
Journal Article
Open access
PDF file
SSSILVIA SAULEDA
SILVIA SAULEDA
MPMaria Piron
Maria Piron
MBMarta Bes
Marta Bes
NMNuria Martinez‐Llonch
Nuria Martinez‐Llonch
LPLuis Puig
Luis Puig
Click on the article title to read more.